RACHEL MAYNARD: Open Payments
NPI 1093467052 · LOUISA, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$951 in 51 payments from 10 companies in 2025. Trend: 2023 $734 · 2024 $1,022 · 2025 $951
Food & beverage: $880Education: $71
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $213 |
| Vanda Pharmaceuticals Inc. | 8 | $167 |
| Alkermes, Inc. | 8 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $143 |
| Teva Pharmaceuticals USA, Inc. | 3 | $102 |
| Neurocrine BioSciences, Inc. | 3 | $65 |
| Janssen Pharmaceuticals, Inc | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $25 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
Products named: ARISTADA, CAPLYTA, REXULTI, ABILIFY ASIMTUFII, FANAPT, INGREZZA, HETLIOZ, INVEGA SUSTENNA.
Industry payments across KY — which companies pay providers there.
